[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 45 of about 45
1. Udhrain A, Skubitz KM, Northfelt DW: Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int J Nanomedicine; 2007;2(3):345-52
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma.
  • Kaposi's sarcoma is a vascular tumor of skin and viscera first described in 1872.
  • Many therapies have been demonstrated to be effective in the treatment of HIV-related Kaposi's sarcoma, including alitretinoin gel, interferon alpha, and various forms of cytotoxic chemotherapy.
  • Antiretroviral therapy combined with cytotoxic agents has yielded significantly greater efficacy than chemotherapy alone.
  • However, as reviewed in this report, pegylated liposomal doxorubicin has been established as the treatment of choice for patients with AIDS-associated Kaposi's sarcoma in Western countries.
  • Compelling preclinical and clinical evidence, reviewed herein, has demonstrated that the nanoparticle (pegylated liposome) delivery system of this formulation leads to greater tumor localization of doxorubicin and consequent improved efficacy, as well as reduced toxicity.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Drug Carriers / chemistry. Herpesvirus 8, Human / drug effects. Liposomes / chemistry. Nanostructures / administration & dosage. Polyethylene Glycols / chemistry. Sarcoma, Kaposi / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):653-9 [9053490.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Aust N Z J Med. 1998 Dec;28(6):777-83 [9972406.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 13):5-15 [15717735.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 13):16-35 [15717736.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3432-7 [10589755.001]
  • [Cites] Oncology (Williston Park). 2000 Jun;14(6):867-78; discussion 878, 881-3, 887- [10887636.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):878-83 [11313176.001]
  • [Cites] Cancer Invest. 2001;19(6):573-80 [11486699.001]
  • [Cites] HIV Clin Trials. 2001 Sep-Oct;2(5):429-37 [11673818.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):399-402 [14752065.001]
  • [Cites] Nature. 1988 Oct 13;335(6191):606-11 [2845275.001]
  • [Cites] BMJ. 1991 Jan 26;302(6770):203-7 [1998759.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):10-4 [8317543.001]
  • [Cites] Lancet. 1993 Aug 21;342(8869):497 [8102452.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(6):372-4 [8305358.001]
  • [Cites] J Acquir Immune Defic Syndr. 1994 May;7(5):463-8 [8158540.001]
  • [Cites] Clin Investig. 1994 Jun;72(6):417-23 [7950152.001]
  • [Cites] Res Virol. 1994 May-Aug;145(3-4):261-9 [7800953.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1994;6(5):294-6 [7530036.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):914-20 [7707119.001]
  • [Cites] Mayo Clin Proc. 1995 Sep;70(9):869-79 [7643641.001]
  • [Cites] Am J Health Syst Pharm. 1995 Sep 15;52(18):2001-4 [8528867.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):989-94 [8611437.001]
  • [Cites] J Clin Pharmacol. 1996 Jan;36(1):55-63 [8932544.001]
  • [Cites] Eur J Med Res. 1998 Feb 21;3(1-2):13-9 [9512962.001]
  • (PMID = 18019833.001).
  • [ISSN] 1176-9114
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols
  • [Number-of-references] 35
  • [Other-IDs] NLM/ PMC2676669
  •  go-up   go-down


2. Jadhav VM, Tolat SN: Dramatic response of propranolol in hemangioma: report of two cases. Indian J Dermatol Venereol Leprol; 2010 Nov-Dec;76(6):691-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic response of propranolol in hemangioma: report of two cases.
  • Hemangiomas are indolent birthmarks of vascular origin, which are known to appear soon after birth, proliferate for 8-18 months, and then slowly regress over the next 5-8 years, leaving behind normal or slightly blemished skin.
  • In rare instances, hemangiomas may encroach upon and endanger vital structures with a mortality of up to 60%.
  • Multiple therapeutic modalities are available for hemangiomas with variable results and associated with side effects.
  • We report two cases of hemangioma, successfully treated with propranolol.
  • Case 1 was a 5-month-old female child who presented with a giant segmental hemangioma since birth.
  • Case 2 was a 1-year-old female child who presented with hemangioma over the danger area of face.
  • Both the cases showed dramatic response, with more than 80% regression, without any relapse after stopping the treatment.
  • [MeSH-major] Hemangioma / diagnosis. Hemangioma / drug therapy. Propranolol / therapeutic use

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21079315.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


3. Sevinir B, Ozkan TB: Infantile hepatic hemangioendothelioma: clinical presentation and treatment. Turk J Gastroenterol; 2007 Sep;18(3):182-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile hepatic hemangioendothelioma: clinical presentation and treatment.
  • BACKGROUND/AIMS: Hepatic hemangioendotheliomas are rare tumors in childhood.
  • RESULTS: The median age at diagnosis was 24 days (age range: 1 to 70 days) and the female/male ratio was 5/3.
  • Cutaneous hemangiomas were present in four cases.
  • Four cases had single hepatic tumors while the others had multiple.
  • The tumor size ranged from 2 cm to 10 cm in diameter.
  • Most of the multifocal hepatic tumors were associated with skin hemangiomas.
  • Treatment options were assessed individually.
  • Systemic prednisolone therapy (2 mg/kg/d) was commenced in six patients.
  • One boy with Kasabach-Merritt syndrome did not respond to this therapy.
  • Interferon-alpha (1 million units (MU)/m2/day) was started, and the daily dose of the drug was increased up to 10 MU/m2, administered 3 times per week, until clinical improvement was achieved.
  • CONCLUSIONS: The treatment approaches depend on the center's experience.
  • A multidisciplinary approach is required for the best treatment option.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Abdomen. Alanine Transaminase / metabolism. Aspartate Aminotransferases / metabolism. Dilatation, Pathologic / etiology. Female. Glucocorticoids / therapeutic use. Hemangioma / diagnosis. Hepatomegaly / etiology. Humans. Immunologic Factors / therapeutic use. Infant. Infant, Newborn. Interferon-alpha / therapeutic use. Male. Neoplasms, Multiple Primary. Prednisolone / therapeutic use. Respiratory Distress Syndrome, Newborn / etiology. Retrospective Studies. Skin Neoplasms / diagnosis. Turkey / epidemiology

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891692.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunologic Factors; 0 / Interferon-alpha; 9PHQ9Y1OLM / Prednisolone; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


Advertisement
4. Zheng JW, Wang YA, Zhou GY, Zhu HG, Ye WM, Zhang ZY: [Head and neck hemangiomas: how and when to treat]. Shanghai Kou Qiang Yi Xue; 2007 Aug;16(4):337-42
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Head and neck hemangiomas: how and when to treat].
  • Hemangiomas are common benign vascular tumors of infancy characterized by a proliferative growth phase followed by very slow inevitable regression (involutive phase) between one to ten years of age, about 60% to 70% of the lesions are found in the head and neck region.
  • There are many treatment modalities reported in the literature for head and neck hemangiomas, including wait and see policy, drug therapy, sclerotherapy (steroids, bleomycin), cryotherapy, isotope radiotherapy, laser therapy, and surgical therapy.
  • There still exist many controversies over the optimal treatment options for individual patient.
  • Based on our clinical experience on 250 cases and literature review, a rational treatment regime for head and neck hemangioma was proposed in this study:.
  • (1) As it is not possible to predict, whether a hemangioma will remain small and unproblematic or grow into a very large lesion, early therapy is the only way out of this dilemma.
  • A white or pink macule, a port-wine stain-like lesion initially appearing in the children can be effectively and easily removed by laser, thus preventing a growth in the size in the early stage. (2) The term of "wait and see" should be substituted by "close observation", and this approach should only be reserved for hemangiomas which are without visible growth or in the involutive phase. (3) Systematic drug therapy (steroids, interferon alpha-2a ) should be considered for large hemangioma, multiple hemangiomas, life-threatening hemangiomas and hemangiomas with complications such as ulceration, infection, bleeding, dysfunction, etc.
  • Congestive heart failure, consumptive coagulopathy, and thrombocytopenia are also urgent indications for the institution of corticoid therapy. (4) Growing hemangioma can be treated effectively by systematic drug therapy, sclerotherapy, laser therapy or combined therapy.
  • The argon laser (514 nm in wavelength, 0.5 mm in depth) is useful in the treatment of superficial telangiectasias and small, flat cutaneous hemangiomas.
  • Flashlamp-pumped pulsed-dye laser (FPDL, 585 nm or 595 nm in wavelength, 1.0-2.0 mm in depth) can be used in patients with cutaneous and flat hemangiomas at the sites of potential functional impairment.
  • Nd: YAG laser (1064 nm in wavelength) with continuous ice cube cooling is useful for subcutaneous or mixed hemangiomas, and often requires repeated treatments.
  • For larger and deeper hemangiomas up to a depth of 2.0 cm, percutaneous interstitial Nd:YAG laser treatment may be preferred, because it may decrease possible cutaneous skin damage and more effectively reduce bulky, deep lesion. (5) Topical application of imiquimoid and intratumoral injection of steroids or bleomycin can be used in selected patients with rapidly growing hemangioma. (6) The indication for a primary operation is rare and limited to large hemangiomas in the eyelid or hemangiomas on the scalp.
  • Surgical correction of large residuals, especially before formal education begins, to prevent considerable psychosocial impairment is still a well established procedure.
  • The aim of treatment is to counter the proliferative growth, reduce the volume of hemangioma, and initialize the process of regression.
  • Cryotherapy or isotope radiotherapy is nowadays seldom used for the treatment of hemangiomas, due to the high incidence of scarring, pigmentation, or depigmentation.
  • A successful treatment of hemangiomas should be individualized and based on the size of the tumor, the localization, and the therapies available.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Hemangioma / therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17924011.001).
  • [ISSN] 1006-7248
  • [Journal-full-title] Shanghai kou qiang yi xue = Shanghai journal of stomatology
  • [ISO-abbreviation] Shanghai Kou Qiang Yi Xue
  • [Language] chi
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  •  go-up   go-down


5. Dourmishev LA, Dourmishev AL: Craniofacial cavernous hemangioma: succesful treatment with methylprednisolone. Acta Dermatovenerol Alp Pannonica Adriat; 2005 Jun;14(2):49-52
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniofacial cavernous hemangioma: succesful treatment with methylprednisolone.
  • Systemic corticosteroid treatment is reported as effective for problematic cutaneous hemangiomas occuring in infancy, and depend on the dose, the duration of treatment, and the age at which the course of drugs is initiated.
  • A 7-month-old female infant with extended cavernous hemangioma on the left part of forehead, face,and neck which appeared 15 days after birth is presented.
  • The oral corticosteroid treatment is an efficient medical therapy for common extended cavernous infantile hemangiomas with accelerated growth if initiated early in the proliferative phase.
  • [MeSH-major] Craniofacial Abnormalities / drug therapy. Glucocorticoids / therapeutic use. Hemangioma, Cavernous / drug therapy. Methylprednisolone / therapeutic use
  • [MeSH-minor] Female. Humans. Infant. Treatment Outcome


6. Nixon BK, Kussick SJ, Carlon MJ, Rubin BP: Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm. Mod Pathol; 2005 Aug;18(8):1121-6
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm.
  • We report the clinicopathological features of two cases of intravascular large B-cell lymphoma involving cutaneous hemangiomas.
  • Both patients were women, 64 and 55 years of age, who presented with long-standing cutaneous hemangiomas of the posterior scalp and left shoulder, respectively.
  • Biopsies and immunohistochemical evaluation of the hemangiomas revealed extensive involvement by intravascular large B-cell lymphoma.
  • Disease was limited to the hemangiomas in both patients.
  • Treatment consisted of chemotherapy (both patients) and adjuvant radiation therapy (one patient).
  • One patient had a recurrence of disease 33 months after initial diagnosis, leading to an autologous stem cell transplant.
  • The other patient is without evidence of disease 27 months after initial diagnosis.
  • Although this is a rare neoplasm, it is important to consider intravascular large B-cell lymphoma in the differential diagnosis of vascular lesions containing intravascular neoplastic cells.
  • [MeSH-major] Hemangioma / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Antigens, CD19 / analysis. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Antigens, CD5 / analysis. DNA-Binding Proteins / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Interferon Regulatory Factors. Middle Aged. Neoplasm Recurrence, Local. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803190.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Antigens, CD5; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / interferon regulatory factor-4; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


7. Pascual-Castroviejo I, Pascual-Pascual SI, Rafia S, Viaño J: [Hemangiomas, and cutaneous and intracranial vascular deformations (Pascual-Castroviejo syndrome tipe II ). A case report]. Rev Neurol; 2002 Dec 1-15;35(11):1034-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemangiomas, and cutaneous and intracranial vascular deformations (Pascual-Castroviejo syndrome tipe II ). A case report].
  • [Transliterated title] Hemangiomas y malformaciones vasculares cutáneas e intracraneales (sindrome de Pascual-Castroviejo tipo II). Presentacion de un caso.
  • OBJECTIVE: To present a case with several cutaneous hemangiomas associated with intracranial hemangiomas and possibly with an intrahepatic hemangioma.
  • CASE REPORT: A boy, 17 months old, showing several cutaneous hemangiomas and epileptic seizures resisting to antiepileptic medication, who also presented psychomotor retardation.
  • The study by angiographic magnetic resonance (AMR ) revealed the presence of three small intracranial angiomas and possibly a hepatic hemangioma.
  • The seizures were controlled with antiepileptic medication.
  • CONCLUSION: This case shows the association of the cutaneous hemangiomas and the subjacent vascular alterations also hemangiomas in this patient which are included in the most frequent neurocutaneous disease, which is known as Pascual Castroviejo syndrome.
  • [MeSH-major] Brain Neoplasms / pathology. Hemangioma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Anticonvulsants / therapeutic use. Humans. Infant. Liver Neoplasms / pathology. Magnetic Resonance Angiography. Male. Psychomotor Disorders. Seizures / drug therapy. Syndrome

  • Genetic Alliance. consumer health - Pascual Castroviejo syndrome.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12497310.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


8. Shen W, Cui J, Chen J, Zou J, Ji Y, Chen H: Kasabach-Merritt syndrome: case reports of successful treatment with partial tumor resection and vincristine chemotherapy. Ann Plast Surg; 2010 Sep;65(3):361-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kasabach-Merritt syndrome: case reports of successful treatment with partial tumor resection and vincristine chemotherapy.
  • The huge tumor is the major cause of rapid platelet destruction, so we supposed the reduction of tumor size could reduce the platelet destruction and improve the clinical condition.
  • In our cases, the vascular tumor occupied one of the extremities, or the head or face.
  • However, removal of the whole tumor would have resulted in the amputation of this extremity or the destruction of the face, and partial tumor removal was suitable.
  • The wound could be repaired with skin graft.
  • Vincristine chemotherapy after the operation was necessary to prevent the enlargement of the remaining tumor.
  • [MeSH-minor] Combined Modality Therapy. Disseminated Intravascular Coagulation / diagnosis. Disseminated Intravascular Coagulation / drug therapy. Disseminated Intravascular Coagulation / surgery. Disseminated Intravascular Coagulation / therapy. Female. Hemangioma, Capillary / diagnosis. Hemangioma, Capillary / drug therapy. Hemangioma, Capillary / surgery. Hemangioma, Capillary / therapy. Humans. Infant, Newborn. Kasabach-Merritt Syndrome. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20733375.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


9. Kim ES, Kim KJ, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK: Metaplastic ossification in a cutaneous pyogenic granuloma: a case report. J Dermatol; 2004 Apr;31(4):326-9
Hazardous Substances Data Bank. TRICHLOROACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic ossification in a cutaneous pyogenic granuloma: a case report.
  • Cutaneous ossification may occur in association with a variety of cutaneous neoplasms and inflammatory conditions, such as pilomatricomas, basal cell carcinomas, nevi, chondroid syringomas, venous stasis, and scars.
  • However, it has rarely been reported in pyogenic granuloma, a relatively common benign vascular tumor of the skin and mucous membranes.
  • We herein presented a rare case of cutaneous pyogenic granuloma with ectopic ossification on the big toe of a 37-year-old man, with high recurrence despite repeated CO2 laser ablations.
  • We propose the hypothesis that vascular endothelial growth factor (VEGF) and bone morphogenetic proteins (BMPs) play pathologic roles in the development of ectopic bone formation in pyogenic granuloma.
  • [MeSH-major] Granuloma, Pyogenic / diagnosis. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Caustics / administration & dosage. Diagnosis, Differential. Drug Administration Schedule. Humans. Laser Therapy. Male. Ossification, Heterotopic / diagnosis. Ossification, Heterotopic / drug therapy. Ossification, Heterotopic / pathology. Ossification, Heterotopic / surgery. Toes. Trichloroacetic Acid / administration & dosage

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15187328.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caustics; 5V2JDO056X / Trichloroacetic Acid
  •  go-up   go-down


10. Hudnall SD, Chen T, Brown K, Angel T, Schwartz MR, Tyring SK: Human herpesvirus-8-positive microvenular hemangioma in POEMS syndrome. Arch Pathol Lab Med; 2003 Aug;127(8):1034-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human herpesvirus-8-positive microvenular hemangioma in POEMS syndrome.
  • We report a case of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome in a 55-year-old African American woman in which human herpesvirus-8 (HHV-8) was demonstrated within rare lymphocytes in a Castleman disease lymph node biopsy and numerous endothelial cells and lymphocytes in a microvenular hemangioma skin biopsy.
  • Initial symptoms and findings of night sweats, weight loss, anorexia, generalized lymphadenopathy, and hemangiomas improved after chemotherapy with cyclophosphamide and prednisone.
  • However, in the year following the initial diagnosis, the patient suffered from recurrent bouts of night sweats, gastroparesis, and lymphadenopathy, which required further treatment with plasmapheresis, cyclophosphamide, prednisone, and rituximab.
  • Although HHV-8 has previously been detected in POEMS-associated Castleman disease tissue, to our knowledge, this is the first case report in which HHV-8 has been directly demonstrated within the endothelial cells of a POEMS-associated hemangioma.
  • [MeSH-major] Hemangioma, Capillary / diagnosis. Hemangioma, Capillary / virology. Herpesviridae Infections / diagnosis. Herpesvirus 8, Human / isolation & purification. POEMS Syndrome / diagnosis. Skin Neoplasms / virology

  • Genetic Alliance. consumer health - Hemangioma.
  • Genetic Alliance. consumer health - POEMS syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12873182.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Chan PT, Lee KC, Chong LY, Lo KK, Cheung YF: Glomeruloid haemangioma with cerebriform morphology in a patient with POEMS syndrome. Clin Exp Dermatol; 2006 Nov;31(6):775-7
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glomeruloid haemangioma with cerebriform morphology in a patient with POEMS syndrome.
  • POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndrome was diagnosed and he was treated with melphalan and prednisolone.
  • After chemotherapy, other manifestations of POEMS syndrome developed, such as multiple haemangiomas over the chest and neck region, splenomegaly and generalized oedema.
  • One haemangioma had a peculiar clinical morphology, similar to the appearance of cerebral gyri.
  • Skin biopsy confirmed the diagnosis of glomeruloid haemangioma.
  • Chemotherapy was then switched to cyclophosphamide and prednisolone, resulting in further improvement in muscle power and hypertrichosis.
  • To our knowledge, this is the first report on a clinically distinctive morphology of glomeruloid haemangioma, and its recognition may increase the index of suspicion for early skin biopsy.
  • [MeSH-major] Hemangioma / pathology. POEMS Syndrome / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Cyclophosphamide / therapeutic use. Drug Therapy, Combination. Humans. Immunosuppressive Agents / therapeutic use. Male. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - POEMS syndrome.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040261.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


12. Nord KM, Kandel J, Lefkowitch JH, Lobritto SJ, Morel KD, North PE, Garzon MC: Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature. Pediatrics; 2006 Sep;118(3):e907-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature.
  • Multiple cutaneous hemangiomas can be associated with internal hemangiomas, with the liver being the most common site.
  • Here we report a case of a premature female neonate who presented with cardiac failure at birth and had typical-appearing infantile hemangiomas on the skin in association with vascular lesions in the liver.
  • Her clinical presentation was felt to be consistent with cutaneous and hepatic infantile hemangiomas.
  • After failure to respond to systemic steroids and chemotherapy, she underwent liver transplantation.
  • Histopathologic evaluation of the liver revealed a diagnosis of type 2 infantile hepatic hemangioendothelioma (regarded as synonymous with angiosarcoma) rather than benign infantile hemangioma of the liver.
  • Subsequent skin biopsies confirmed that her multiple cutaneous lesions were infantile hemangiomas and not metastatic angiosarcoma.
  • We report this case and a review of the literature on pediatric angiosarcoma of the liver associated with cutaneous infantile hemangiomas.
  • [MeSH-major] Hemangioma / pathology. Hemangiosarcoma / pathology. Liver Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatrics. 2007 Jun;119(6):1271
  • (PMID = 16880251.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


13. Chen CC, Kong MS, Yang CP, Hung IJ: Hepatic hemangioendothelioma in children: analysis of thirteen cases. Acta Paediatr Taiwan; 2003 Jan-Feb;44(1):8-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatic hemangioendothelioma (HE) is a tumor that presents in infancy and toddler.
  • The diagnosis was made by the histology specimen or various imaging studies.
  • The common clinical manifestations included abdominal distention (53%), congestive heart failure (38.5%), abdominal mass (30.8%), jaundice (30.8%), and skin hemangioma (23.1%).
  • Computed tomography (n = 11) revealed central hypointensity with peripheral enhancement after contrast of the liver masses.
  • Other management included interferon, chemotherapy, embolization and/or surgery.
  • Among the other nine patients, four patients died of sepsis, hepatic failure, disseminated intravascular coagulopathy or tumor rupture with hemorrhagic shock.
  • HE appears to be a histologically benign tumor but may have a poor outcome because of complications.
  • For its management, steroid is a first-line medication.
  • Other methods of treatment were interferon, hepatic artery embolization, chemotherapy and surgery.
  • Long term follow up is needed for the evaluation of treatment response.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12800377.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


14. O TM, Alexander RE, Lando T, Grant NN, Perkins JA, Blitzer A, Waner M: Segmental hemangiomas of the upper airway. Laryngoscope; 2009 Nov;119(11):2242-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmental hemangiomas of the upper airway.
  • OBJECTIVES/HYPOTHESIS: To characterize the anatomic distribution of segmental hemangiomas of the larynx and to describe indications for treatment modalities.
  • METHODS: We performed a retrospective chart review of patients with cutaneous hemangiomas at a tertiary care center over a 4-year period.
  • Only patients with upper airway hemangiomas were studied.
  • We reviewed the anatomic distribution of hemangiomas within the upper airway and the treatment course of each patient.
  • RESULTS: Of 1,226 patients with cutaneous hemangiomas, 108 (9%) were segmental in distribution.
  • All of these patients had associated V3 or mandibular segmental hemangiomas.
  • As with the cutaneous manifestation, the distribution of hemangioma within the upper airway was segmental.
  • One patient received chemotherapy prior to referral.
  • Surgical treatment included tracheostomy (four patients prior to referral) and laser ablation of subglottic involvement (total of four patients).
  • CONCLUSIONS: A high percentage of patients with V3 cutaneous hemangiomas (29%) will manifest with upper airway involvement, the distribution of which is segmental.
  • Treatment should take this diffuse pattern of involvement into consideration.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Hemangioma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806648.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kurian S, Ertan E, Ducatman B, Crowell EB, Rassekh C: Esthesioneuroblastoma in Maffucci's syndrome. Skeletal Radiol; 2004 Oct;33(10):609-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maffucci's syndrome consists of multiple cutaneous hemangiomas, dyschondroplasia, and enchondromas with potential for malignant change.
  • Radiological studies showed a large soft tissue mass centered in the sinonasal area, extending bilaterally into maxillary sinuses and orbits with compression of left optic nerve.
  • Chemotherapy resulted in initial improvement, but the tumor recurred and did not respond to further treatment, resulting in his death.
  • Sarcomatous tumors are reported in Maffucci's syndrome, but this is a rare case of a neuroendocrine tumor in a patient with Maffucci's syndrome.
  • [MeSH-major] Enchondromatosis / complications. Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity / pathology. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Maxillary Sinus Neoplasms / diagnosis. Neoplasm Recurrence, Local / pathology. Orbital Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Am J Clin Oncol. 1990 Apr;13(2):139-43 [2180272.001]
  • [Cites] Arch Otolaryngol. 1979 Jul;105(7):427-30 [454301.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Jun;15(6):1169-77 [8073990.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):73-8 [7712654.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):34-40 [9006501.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15221218.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Rodriguez V, Lee A, Witman PM, Anderson PA: Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol; 2009 Jul;31(7):522-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kasabach-Merritt phenomenon (KMP) is a rare thrombocytopenic consumption coagulopathy associated with an enlarging tufted angioma or kaposiform hemangioendothelioma.
  • We report a case series of patients with KMP and discuss the treatment options and outcomes.
  • Nine patients with a diagnosis of KMP were identified through retrospective chart review-6 had "definite KMP" and 3 had "less likely KMP."
  • The hematologic features of KMP and those of chronic coagulopathy seen with other vascular malformations can be similar, which makes KMP difficult to distinguish.
  • [MeSH-major] Disseminated Intravascular Coagulation / complications. Disseminated Intravascular Coagulation / physiopathology. Hemangioendothelioma / complications. Hemangioma / complications. Skin Neoplasms / complications
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Humans. Infant. Male. Radiotherapy. Thrombocytopenia / complications. Thrombocytopenia / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564750.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents
  • [Number-of-references] 10
  •  go-up   go-down


17. Mazereeuw-Hautier J: [What's new in pediatric dermatology?]. Ann Dermatol Venereol; 2009 Dec;136 Suppl 7:S426-35
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Quoi de neuf en dermatologie pédiatrique?
  • There are also new data on therapy using tacrolimus.
  • With regards to vascular anomalies and especially haemangiomas, the literature comprises new data on evolution and efficacy of propranolol.
  • With regards to congenital nevi, there are studies related to treatment and complications.
  • With regards to warts, the literature brings news about virus transmission and therapy.
  • With regards to genodermatosis (neurofibromatosis type I, cutis laxa, pseudoxanthoma elasticum, epidermolysis bullosa, ichtyoses and pilar diseases), we found novel facts in the fields of molecular analysis, clinical aspects, pathophysiology and quality of life.
  • [MeSH-major] Dermatologic Agents / therapeutic use. Dermatology / trends. Skin Diseases / diagnosis. Skin Diseases / drug therapy
  • [MeSH-minor] Alopecia Areata / diagnosis. Alopecia Areata / drug therapy. Child. Dermatitis, Atopic / diagnosis. Dermatitis, Atopic / drug therapy. Evidence-Based Medicine. Hemangioma / diagnosis. Hemangioma / drug therapy. Humans. Mucocutaneous Lymph Node Syndrome / diagnosis. Mucocutaneous Lymph Node Syndrome / drug therapy. Nevus / diagnosis. Nevus / drug therapy. Pityriasis Rubra Pilaris / diagnosis. Pityriasis Rubra Pilaris / drug therapy. Psoriasis / diagnosis. Psoriasis / drug therapy. Quality of Life. Randomized Controlled Trials as Topic. Risk Factors. Skin Diseases, Genetic / diagnosis. Skin Diseases, Genetic / drug therapy. Skin Diseases, Viral / diagnosis. Skin Diseases, Viral / drug therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy. Stevens-Johnson Syndrome / diagnosis. Stevens-Johnson Syndrome / drug therapy. Urticaria / diagnosis. Urticaria / drug therapy. Vitiligo / diagnosis. Vitiligo / drug therapy. Warts / diagnosis. Warts / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20110058.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dermatologic Agents
  • [Number-of-references] 71
  •  go-up   go-down


18. Djilali-Bouzina F, Grange F, Krzisch S, Schnebelen MP, Grosshans E, Guillaume JC: [Annular elastolytic giant cell granuloma]. Ann Dermatol Venereol; 2010 Aug-Sep;137(8-9):536-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a favourable outcome in a case of AEGCG following PUVA therapy and treatment with synthetic antimalarials.
  • Various topical treatments proved ineffective and systemic corticosteroids attenuated the patient's pruritus but had no effect on the skin lesions.
  • PUVA therapy resulted in regression of lesions on the trunk, but the rash spread to the patient's arms and was covered with epidermal microcysts.
  • PUVA therapy was discontinued and treatment with a synthetic antimalarial (hydroxychloroquine 400mg/d) was initiated, resulting in complete regression of the lesions.
  • The aetiology is unknown and treatment is empirical.
  • Spontaneous cure can occur and consistent results have not been obtained with any treatments.
  • [MeSH-major] Elastic Tissue / pathology. Granuloma Annulare / diagnosis. Granuloma, Giant Cell / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Aged. Antimalarials / therapeutic use. Antipruritics / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Hemangioma / complications. Humans. Hydroxychloroquine / therapeutic use. Incidental Findings. Liver Neoplasms / complications. Male. PUVA Therapy. Pruritus / drug therapy. Pruritus / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Masson SAS.
  • (PMID = 20804898.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antimalarials; 0 / Antipruritics; 4QWG6N8QKH / Hydroxychloroquine
  •  go-up   go-down


19. Selim H, Selim A, Khachemoune A, Metwally SA: Use of sclerosing agent in the management of oral and perioral hemangiomas: review and case reports. Med Sci Monit; 2007 Sep;13(9):CS114-119
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of sclerosing agent in the management of oral and perioral hemangiomas: review and case reports.
  • BACKGROUND: Most cutaneous hemangiomas involute spontaneously.
  • CASE REPORTS: Three hemangioma cases were treated by repeated local injection of 5% ethanolamine oleate solution.
  • CONCLUSIONS: Use of 5% ethanolamine oleate as a sclerosing agent for repeated intralesional injection in the management of facial hemangiomas is a safe treatment with acceptable results.
  • [MeSH-major] Hemangioma / drug therapy. Hemangioma / pathology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Sclerosing Solutions / therapeutic use. Sclerotherapy
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Infant. Tomography Scanners, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17767124.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Sclerosing Solutions
  • [Number-of-references] 32
  •  go-up   go-down


20. Garzon MC, Lucky AW, Hawrot A, Frieden IJ: Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol; 2005 Feb;52(2):281-6
Hazardous Substances Data Bank. BETAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrapotent topical corticosteroid treatment of hemangiomas of infancy.
  • BACKGROUND: Superficial cutaneous hemangiomas of infancy represent a therapeutic challenge.
  • Two small case series using ultrapotent topical corticosteroids for periocular hemangiomas were reported in the ophthalmologic literature.
  • The use of this therapy for hemangiomas of infancy at other sites on the body has not been reported.
  • OBJECTIVE: We sought to assess the clinical effects of short-term application of ultrapotent topical corticosteroids for the treatment of hemangiomas of infancy.
  • METHODS: The records of 34 infants with proliferating hemangiomas of infancy that were treated with ultrapotent topical steroids were reviewed retrospectively.
  • Treatment response was based on:.
  • CONCLUSIONS: Hemangiomas in 74% of the infants demonstrated either good or partial response to treatment with ultrapotent topical corticosteroids.
  • Improvement varied, with thinner superficial hemangiomas demonstrating better cosmetic improvement than thicker lesions.
  • [MeSH-major] Betamethasone / analogs & derivatives. Clobetasol / analogs & derivatives. Hemangioma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Extremities. Eye Neoplasms / drug therapy. Eyelids. Facial Neoplasms / drug therapy. Female. Humans. Infant. Infant, Newborn. Male. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Clobetasol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692474.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 826Y60901U / betamethasone-17,21-dipropionate; 9842X06Q6M / Betamethasone; 9P6159HM7T / halobetasol; ADN79D536H / Clobetasol
  • [Number-of-references] 14
  •  go-up   go-down


21. Atten MJ, Ahmed S, Attar BM, Richter H 3rd, Mehta B: Massive pelvic hemangioma in a patient with blue rubber bleb nevus syndrome. South Med J; 2000 Nov;93(11):1122-5
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive pelvic hemangioma in a patient with blue rubber bleb nevus syndrome.
  • Blue rubber bleb nevus syndrome (BRBNS) is a rare disorder characterized by gastrointestinal and cutaneous hemangiomas.
  • We describe a patient with BRBNS and lower gastrointestinal bleeding resulting from a large pelvic hemangioma eroding into the rectal wall.
  • [MeSH-major] Hemangioma / etiology. Nevus, Blue / complications. Pelvic Neoplasms / etiology
  • [MeSH-minor] Adult. Anemia, Iron-Deficiency / drug therapy. Anemia, Iron-Deficiency / etiology. Dietary Supplements. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iron / therapeutic use. Neoplasm Invasiveness. Rectum / pathology. Syndrome


22. Wananukul S, Voramethkul W, Nuchprayoon I, Seksarn P: Diffuse Neonatal Hemangiomatosis: report of 5 cases. J Med Assoc Thai; 2006 Aug;89(8):1297-303
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse Neonatal Hemangiomatosis (DNH) is a rare, life-threatening condition associated with a few to hundreds of small, cutaneous and visceral hemangiomas.
  • The authors reported 5 cases of DNH in which hepatic hemangioma were the most common visceral involvement.
  • Response to prednisolone in these cases was not good, one died and four required second line therapy.
  • [MeSH-major] Angiomatosis / diagnosis. Angiomatosis / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Hemangioma / diagnosis. Hemangioma / drug therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Prednisolone / therapeutic use. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Diffuse Neonatal Hemangiomatosis.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048444.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


23. Jalil S, Akhtar J, Ahmed S: Corticosteroids therapy in the management of infantile cutaneous hemangiomas. J Coll Physicians Surg Pak; 2006 Oct;16(10):662-5
Hazardous Substances Data Bank. TRIAMCINOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corticosteroids therapy in the management of infantile cutaneous hemangiomas.
  • OBJECTIVE: To determine the effectiveness of systemic and intra-lesional corticosteroids, in the management of infantile cutaneous hemangiomas and to compare the results with untreated lesions.
  • PATIENTS AND METHODS: A total of 75 cases with cutaneous hemangiomas were included in the study.
  • Outcome measures noted were the change in size before and after treatment, duration of proliferative phase, change in morphology and complications.
  • CONCLUSION: Hemangiomas when left untreated behave in an unpredictable manner.
  • [MeSH-major] Glucocorticoids / administration & dosage. Hemangioma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007757.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Glucocorticoids; 1ZK20VI6TY / Triamcinolone
  •  go-up   go-down


24. Soeda A, Sakai N, Iihara K, Nagata I: Cobb syndrome in an infant: treatment with endovascular embolization and corticosteroid therapy: case report. Neurosurgery; 2003 Mar;52(3):711-5; discussion 714-5
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cobb syndrome in an infant: treatment with endovascular embolization and corticosteroid therapy: case report.
  • OBJECTIVE AND IMPORTANCE: Cobb syndrome is a rare clinical entity characterized by the combination of a vascular skin nevus and an angioma in the spinal canal at the same metamere.
  • CLINICAL PRESENTATION: A 5-month-old girl presented with cutaneous hemangioma of the thoracolumbar region (T5-T12) and paraparesis.
  • INTERVENTION: The patient received orally administered prednisolone therapy and underwent endovascular embolization of paravertebral and spinal angiomas with the use of n-butyl-2-cyanoacrylate.
  • Her symptoms improved by combined treatment with liquid embolization and corticosteroid therapy.
  • To our knowledge, this is the first report of an infant with Cobb syndrome treated with endovascular embolization and corticosteroid therapy.
  • The combined treatment with corticosteroid therapy and endovascular embolization of cutaneomeningospinal angioma in Cobb syndrome seems effective in alleviating symptoms and minimizing morbidity.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Embolization, Therapeutic. Hemangioma / complications. Hemangioma / therapy. Nevus / complications. Nevus / therapy. Prednisolone / therapeutic use. Skin Neoplasms / complications. Skin Neoplasms / therapy. Spinal Canal / drug effects. Spinal Canal / surgery. Spinal Neoplasms / complications. Spinal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12590699.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


25. Verma K, Verma KK: Infantile periocular haemangioma treated with two days in a week betamethasone oral mini pulse therapy. Indian J Pediatr; 2001 Apr;68(4):355-6
Hazardous Substances Data Bank. BETAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile periocular haemangioma treated with two days in a week betamethasone oral mini pulse therapy.
  • On cutaneous examination there was a large brightly erythematous, lobulated, soft plaque on the right side of the forehead of 12 cm x 10 cm, involving the right upper eyelid obscuring the visual axis and extending on to the right upper lip.
  • Computed tomography of head and orbit confirmed the diagnosis of capillary haemangioma.
  • [MeSH-major] Betamethasone / therapeutic use. Glucocorticoids / therapeutic use. Hemangioma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Dermatol Venereol Leprol. 2000 Jan-Feb;66(1):34-5 [20877018.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 1996 Mar-Apr;62(2):106-9 [20947995.001]
  • [Cites] J AAPOS. 1997 Dec;1(4):226-30 [10532768.001]
  • [Cites] Int J Dermatol. 1993 Oct;32(10):753-7 [8225724.001]
  • [Cites] Int Surg. 1997 Jan-Mar;82(1):49-51 [9189802.001]
  • [Cites] J Am Acad Dermatol. 1986 Feb;14(2 Pt 1):161-77 [3512634.001]
  • [Cites] Surv Ophthalmol. 1994 Mar-Apr;38(5):399-426 [8009426.001]
  • (PMID = 11370446.001).
  • [ISSN] 0019-5456
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Glucocorticoids; 9842X06Q6M / Betamethasone
  •  go-up   go-down


26. Rosbe KW, Suh KY, Meyer AK, Maguiness SM, Frieden IJ: Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg; 2010 Jul;136(7):658-65
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Propranolol in the management of airway infantile hemangiomas.
  • OBJECTIVE: To report our experience with propranolol in managing airway infantile hemangiomas.
  • DESIGN: Case series of 3 consecutive patients who had extensive, symptomatic airway infantile hemangiomas treated with propranolol.
  • PATIENTS: Three infants with facial cutaneous hemangiomas who developed stridor that progressed to respiratory distress, which according to laryngoscopic examination results was confirmed to be caused by extensive subglottic hemangiomas.
  • These patients underwent follow-up during their course of therapy, ranging from 3 weeks to 15 months.
  • RESULTS: Patient 1 failed to respond to systemic corticosteroids, laser ablation, and intravenous vincristine for her airway hemangioma and had to undergo tracheotomy.
  • Patient 2 developed progressive stridor secondary to airway hemangioma at age 6 1/2 months following tapering of systemic corticosteroids prescribed for her periorbital hemangioma.
  • Patient 3 was also treated with initial combined therapy of systemic corticosteroids and propranolol.
  • CONCLUSIONS: Our 3 patients had severe respiratory symptoms related to their airway infantile hemangiomas.
  • In the first patient, propranolol was used when other treatments were ineffective or associated with intolerable adverse effects.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Glottis / pathology. Hemangioma / drug therapy. Laryngeal Neoplasms / drug therapy. Propranolol / therapeutic use
  • [MeSH-minor] Airway Obstruction / congenital. Airway Obstruction / therapy. Combined Modality Therapy. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Laryngoscopy. Male. Risk Assessment. Sampling Studies. Skin Neoplasms / congenital. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy. Tracheostomy / methods. Treatment Outcome


27. Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E, Staiano A: Blue rubber bleb nevus syndrome. Acta Paediatr; 2010 Apr;99(4):632-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blue rubber bleb nevus syndrome.
  • Blue Rubber Bleb Nevus Syndrome (BRBNS) is a rare condition characterized by multiple venous malformations involving the skin and internal organs.
  • Endoscopy is the gold standard technique for the diagnosis of BRBNS with GI lesions and also allows immediate therapeutic measures such as argon plasma coagulation, laser photocoagulation, sclerotherapy or band ligation.
  • In addition, pharmacological treatments based on corticosteroids, interferon alfa, vincristine or octreotide have been described for BRBNS.
  • CONCLUSION: Blue Rubber Bleb Nevus Syndrome is a congenital cutaneous and gastrointestinal haemangiomatosis.
  • The treatment is based on pharmacological or surgical therapy.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Hemangioma / pathology. Nevus, Blue / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Blue Rubber Bleb Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958301.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


28. Rudnick EF, Chen EY, Manning SC, Perkins JA: PHACES syndrome: otolaryngic considerations in recognition and management. Int J Pediatr Otorhinolaryngol; 2009 Feb;73(2):281-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children with segmental facial hemangiomas of infancy and one extracutaneous manifestation comprising PHACES (posterior fossa malformation, arteriovenous malformations, cardiac/aortic defects, eye anomalies, and sternal defect) were identified.
  • Treatment for cutaneous and airway hemangiomas included oral and intralesional steroids, CO(2) or pulse-dye laser, tracheotomy, and surgical excision.
  • RESULTS: Of 246 children with segmental facial hemangiomas of infancy evaluated since January 2000, 5 girls (2.0%) met diagnostic criteria for PHACES.
  • Otolaryngic abnormalities included middle ear atelectasis (1/5), tympanic membrane hemangiomas with conductive hearing loss (3/5), skin and cartilage ulceration (2/5), dysphagia (4/5), and airway hemangiomas with stridor (3/5).
  • Three children received oral steroids and required pulse-dye laser for cutaneous hemangiomas of infancy.
  • Additional interventions included tympanostomy tubes and resection of nasal hemangioma.
  • CONCLUSIONS: Diagnosis of PHACES requires awareness of the association of facial hemangiomas of infancy with systemic and airway problems.
  • [MeSH-major] Abnormalities, Multiple / diagnosis. Hemangioma / diagnosis. Otorhinolaryngologic Diseases / diagnosis
  • [MeSH-minor] Cardiovascular Abnormalities / diagnosis. Cranial Fossa, Posterior / abnormalities. Facial Neoplasms / diagnosis. Facial Neoplasms / drug therapy. Facial Neoplasms / surgery. Female. Glucocorticoids / therapeutic use. Heart Defects, Congenital / diagnosis. Humans. Infant. Infant, Newborn. Intracranial Arteriovenous Malformations / diagnosis. Laser Therapy. Lip Neoplasms / diagnosis. Lip Neoplasms / surgery. Lip Neoplasms / therapy. Retrospective Studies. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery. Syndrome. Tracheal Neoplasms / diagnosis. Tracheal Neoplasms / drug therapy. Tracheal Neoplasms / surgery. Tracheotomy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081148.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


29. Senchak AJ, Dann M, Cable B, Bessinger G: Successful treatment of cutaneous hemangioma of infancy with topical imiquimod 5%: a report of 3 cases. Ear Nose Throat J; 2010 Mar;89(3):E21-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of cutaneous hemangioma of infancy with topical imiquimod 5%: a report of 3 cases.
  • Hemangioma of infancy is the most common benign tumor of childhood.
  • Most of these tumors spontaneously regress over several years.
  • However, many parents seek treatment for children with cutaneous hemangiomas because of the potential for disfigurement and the attendant psychosocial effects.
  • We report our use of the nightly application of topical imiquimod 5% cream as an alternative to traditional management in 3 infants who presented with rapidly growing facial hemangiomas.
  • After approximately 3 to 5 months of treatment, all 3 patients had experienced a near-complete resolution of their lesions without significant side effects.
  • Based on our experience, we believe that topical imiquimod may be an important tool for the otolaryngologist who treats cutaneous hemangiomas.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Hemangioma / drug therapy. Hemangioma / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20229466.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


30. Fulkerson DH, Agim NG, Al-Shamy G, Metry DW, Izaddoost SA, Jea A: Emergent medical and surgical management of mediastinal infantile hemangioma with symptomatic spinal cord compression: case report and literature review. Childs Nerv Syst; 2010 Dec;26(12):1799-805
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergent medical and surgical management of mediastinal infantile hemangioma with symptomatic spinal cord compression: case report and literature review.
  • PURPOSE: We report an extremely rare case of a patient with a large, cervical, and upper thoracic cutaneous hemangioma associated with a separate, underlying mediastinal hemangioma extending to the epidural space causing significant spinal cord compression.
  • She underwent emergent surgical decompression and medical therapy with propranolol and systemic corticosteroids.
  • CONCLUSION: While several recent reports have described dramatic responses of hemangiomas to propranolol, this is the first case in which it was used as part of a multimodal approach to symptomatic spinal cord compression.
  • She is neurologically intact and has radiographic regression of the hemangiomas on follow-up examination 6 months later.
  • [MeSH-major] Decompression, Surgical / adverse effects. Hemangioma, Capillary / drug therapy. Hemangioma, Capillary / surgery. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / surgery. Spinal Cord Compression / surgery
  • [MeSH-minor] Adrenergic beta-Antagonists / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Anticoagulants / therapeutic use. Child, Preschool. Female. Heparin / therapeutic use. Humans. Postoperative Complications / drug therapy. Postoperative Complications / etiology. Prednisolone / therapeutic use. Propranolol / therapeutic use. Venous Thrombosis / drug therapy. Venous Thrombosis / etiology

  • Genetic Alliance. consumer health - Hemangioma.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet A. 2006 May 1;140(9):975-86 [16575892.001]
  • [Cites] Pediatrics. 2009 Nov;124(5):1447-56 [19858157.001]
  • [Cites] Arch Dermatol. 2001 Sep;137(9):1208-13 [11559219.001]
  • [Cites] N Engl J Med. 1992 May 28;326(22):1456-63 [1489383.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):416-21 [7705821.001]
  • [Cites] Pediatr Dermatol. 2009 Sep-Oct;26(5):610-4 [19840322.001]
  • [Cites] N Engl J Med. 2008 Jun 12;358(24):2649-51 [18550886.001]
  • [Cites] J Pediatr. 1968 Mar;72(3):351-7 [5639749.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):882-7 [16950977.001]
  • [Cites] J Pediatr Surg. 1992 Oct;27(10):1291-3 [1403505.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2002 May;38(5):298-304 [12418927.001]
  • [Cites] Pediatrics. 2009 Sep;124(3):e423-31 [19706583.001]
  • [Cites] Pediatr Dermatol. 2005 Sep-Oct;22(5):383-406 [16190987.001]
  • [Cites] Arch Dermatol. 1977 Nov;113(11):1587-90 [931402.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2009 Dec;73(12):1821-3 [19796830.001]
  • [Cites] Arch Dermatol. 2010 Dec;146(12):1391-6 [20713775.001]
  • [Cites] Arch Dermatol. 2002 Dec;138(12):1567-76 [12472344.001]
  • [Cites] N Engl J Med. 2008 Dec 25;359(26):2846; author reply 2846-7 [19109584.001]
  • [Cites] Neuroradiology. 1978;16:82-4 [740218.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1465-6 [19453811.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):11-22 [10665907.001]
  • [Cites] J Pediatr. 1997 Oct;131(4):643-6 [9386676.001]
  • [Cites] Pediatrics. 1989 Jun;83(6):977-80 [2657627.001]
  • [Cites] Neuropediatrics. 1990 Aug;21(3):160-1 [2234322.001]
  • [Cites] Pediatr Dermatol. 2008 Mar-Apr;25(2):168-73 [18429772.001]
  • [Cites] J Neurosurg Pediatr. 2009 May;3(5):429-34 [19409024.001]
  • [Cites] Arch Dermatol. 2004 May;140(5):591-6 [15148105.001]
  • [Cites] Pediatr Neurol. 2008 Dec;39(6):423-5 [19027589.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2009 Aug;73(8):1168-72 [19481268.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 May;30(5):1005-13 [19213817.001]
  • [Cites] Ann Surg. 1915 Dec;62(6):641-9 [17863459.001]
  • [Cites] Pediatr Radiol. 1999 Jul;29(7):517-9 [10398787.001]
  • [Cites] J Neurosurg Spine. 2005 Sep;3(3):249-52 [16235712.001]
  • [Cites] J Am Acad Dermatol. 2003 Apr;48(4):477-93; quiz 494-6 [12664009.001]
  • [Cites] J Dtsch Dermatol Ges. 2010 Mar;8(3):184-6 [19788583.001]
  • [Cites] Pediatr Dermatol. 2008 Mar-Apr;25(2):193-5 [18429777.001]
  • [Cites] Laryngoscope. 2009 Oct;119(10):2051-4 [19650125.001]
  • [Cites] Plast Reconstr Surg. 1967 Jan;39(1):76-83 [6018814.001]
  • [Cites] Eur J Pediatr Surg. 2002 Dec;12(6):366-74 [12548487.001]
  • (PMID = 20405131.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Anti-Inflammatory Agents; 0 / Anticoagulants; 9005-49-6 / Heparin; 9PHQ9Y1OLM / Prednisolone; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


31. Ho V, Krol A, Bhargava R, Osiovich H: Diffuse neonatal haemangiomatosis. J Paediatr Child Health; 2000 Jun;36(3):286-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Hemangioma / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Central Nervous System Venous Angioma / diagnosis. Central Nervous System Venous Angioma / drug therapy. Drug Therapy, Combination. Fatal Outcome. Female. Humans. Infant, Newborn. Interferon-alpha / administration & dosage. Magnetic Resonance Imaging. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10849236.001).
  • [ISSN] 1034-4810
  • [Journal-full-title] Journal of paediatrics and child health
  • [ISO-abbreviation] J Paediatr Child Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


32. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ: Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol; 2001 Sep;137(9):1208-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation.
  • OBJECTIVES: To determine the efficacy of systemic corticosteroid therapy in treating enlarging, problematic cutaneous hemangiomas and to assess the relationship of dose to response and adverse effects.
  • PATIENTS: Inclusion criteria were original case series with a minimum of 5 patients with enlarging, problematic cutaneous hemangiomas treated with systemic corticosteroids.
  • Exclusion criteria were being older than 2 years, receiving simultaneous other treatments, being lost to follow-up, or having insufficient information.
  • CONCLUSION: Systemic corticosteroid treatment seems to be effective for problematic cutaneous hemangiomas of infancy.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Evidence-Based Medicine. Hemangioma / drug therapy
  • [MeSH-minor] Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Steroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11559219.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


33. Munakata S, Hirano S, Yoshiyama Y, Koizumi M, Kobayasi T, Hattori T: [Beneficial effects of CHOP therapy in a case of intravascular large B-cell lymphoma diagnosed by skin biopsy]. Rinsho Shinkeigaku; 2000 May;40(5):476-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Beneficial effects of CHOP therapy in a case of intravascular large B-cell lymphoma diagnosed by skin biopsy].
  • A 52-year-old man gradually developed dementia and abnormal behaviors, which were later accompanied by spastic paraplegia and sensory disturbance in his lower limbs.
  • Many skin rashes that looked like senile hemangioma were observed on his body.
  • Several of those were biopsied, and the diagnosis of intravascular large B-cell lymphoma was made because of malignant B lymphocytes filling the vessel lumens in one of the seven biopsy specimens.
  • CHOP therapy was performed and found to be effective for the neurological disorders such as dementia, paraplegia, and sensory disturbance.
  • Our case suggests that skin biopsy for more than one sample of the skin rashes is very important for the diagnosis of intravascular large B-cell lymphoma.
  • CHOP therapy might be effective in this case because of early diagnosis by skin biopsy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Skin / pathology. Vascular Neoplasms / drug therapy
  • [MeSH-minor] Biopsy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11002731.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


34. Tamai N, Hashii Y, Osuga K, Chihara T, Morii E, Aozasa K, Yoshikawa H: Kaposiform hemangioendothelioma arising in the deltoid muscle without the Kasabach-Merritt phenomenon. Skeletal Radiol; 2010 Oct;39(10):1043-6
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposiform hemangioendothelioma (KHE) is a rare tumor that occurs nearly exclusively during infancy and childhood.
  • It has features common to both capillary hemangioma and Kaposi sarcoma and for that reason many terms have been used for these tumors including "Kaposi-like infantile hemangioendothelioma" and "hemangioma with Kaposi sarcoma-like features."
  • Knowledge of the radiological findings of this uncommon tumor might be helpful for diagnosis.
  • We present the MRI features of a case of KHE with neither typical skin lesions nor the Kasabach-Merritt phenomenon.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Deltoid Muscle / pathology. Deltoid Muscle / ultrastructure. Diagnosis, Differential. Disseminated Intravascular Coagulation. Hemangioendothelioma / diagnosis. Hemangioendothelioma / drug therapy. Hemangioendothelioma / ultrastructure. Hemangioma, Capillary. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / drug therapy. Hemangioma, Cavernous / ultrastructure. Humans. Infant. Kasabach-Merritt Syndrome. Magnetic Resonance Imaging / methods. Male. Prednisolone / therapeutic use. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / ultrastructure. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy. Skin Neoplasms / ultrastructure. Thrombocytopenia / diagnosis. Thrombocytopenia / drug therapy. Treatment Outcome. Vascular Neoplasms / diagnosis. Vascular Neoplasms / drug therapy. Vascular Neoplasms / ultrastructure

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Genetic Alliance. consumer health - Kaposiform Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):616-22 [15793511.001]
  • [Cites] Head Neck. 2006 Aug;28(8):761-4 [16721737.001]
  • [Cites] Skeletal Radiol. 2009 Jun;38(6):535-47 [19020874.001]
  • [Cites] J Pediatr Surg. 2006 Aug;41(8):1486-8 [16863862.001]
  • [Cites] Adv Anat Pathol. 2003 Mar;10(2):69-87 [12605089.001]
  • [Cites] Adv Dermatol. 1997;13:375-423 [9551150.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):321-8 [8494101.001]
  • [Cites] Br J Plast Surg. 2002 Mar;55(2):163-5 [11987956.001]
  • [Cites] Dermatol Clin. 1998 Jul;16(3):455-88 [9704205.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):931-3 [16611794.001]
  • [Cites] Skeletal Radiol. 1997 Nov;26(11):654-8 [9428073.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):559-68 [15105642.001]
  • [Cites] J Pediatr Surg. 2008 Jan;43(1):e37-41 [18206444.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1087-92 [11706068.001]
  • [Cites] Br J Radiol. 2009 Mar;82(975):e51-4 [19211904.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):225-35 [10642677.001]
  • [Cites] Skeletal Radiol. 2006 Mar;35(3):127-37 [16447042.001]
  • [Cites] Skeletal Radiol. 2004 Jul;33(7):409-12 [15205928.001]
  • (PMID = 20309545.001).
  • [ISSN] 1432-2161
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 9PHQ9Y1OLM / Prednisolone; Kaposiform Hemangioendothelioma
  •  go-up   go-down


35. Omidvari S, Nezakatgoo N, Ahmadloo N, Mohammadianpanah M, Mosalaei A: Role of intralesional bleomycin in the treatment of complicated hemangiomas: prospective clinical study. Dermatol Surg; 2005 May;31(5):499-501
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of intralesional bleomycin in the treatment of complicated hemangiomas: prospective clinical study.
  • BACKGROUND: Hemangioma is the most common tumor of infancy.
  • Although it has a basically benign nature and usually spontaneously regresses, a small percentage (5%) have complications that need treatment.
  • Many different therapeutic modalities can be used in this tumor.
  • OBJECTIVE: To investigate the effect of a new method of treatment (intralesional bleomycin injection) in complicated hemangiomas.
  • MATERIALS AND METHODS: In the Department of Radiation Oncology at Nemazee Hospital in Shiraz, Iran, from April 1992 to October 1998, 32 patients with complicated hemangioma were treated with four to six courses of direct injection of bleomycin into the lesion.
  • CONCLUSION: Intralesional injection of bleomycin is an easy, safe, and effective therapeutic modality in complicated cutaneous hemangiomas.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Hemangioma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Injections, Intralesional. Male. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962730.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


36. Akyüz C, Yariş N, Kutluk MT, Büyükpamukçu M: Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. Pediatr Hematol Oncol; 2001 Jan-Feb;18(1):47-55
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy.
  • The effectiveness of the different pharmacological agents and different doses of systemic corticosteroids was analyzed.
  • A total of 1109 patients (median age 8 months; F/M: 2.3) with hemangioma, followed up in our unit for 23 years, were evaluated retrospectively.
  • Two different pharmacological agents, prednisolone (in 26 patients) and methyl prednisolone (in 19 patients), had been used in three different regimens.
  • Then were no differences in response to therapy among the three regimens.
  • No difference was found in response to therapy between prednisolone and methylprednisolone and the two different doses of the methylprednisolone.
  • In multivariate analysis the dimension of the lesion (p = .0065) and age at initiation of treatment (p = .0041) were the most important factors affecting the response.
  • In conclusion, the systemic corticosteroids are effective in 36% of patients, independent of dosage and pharmacological agents and duration of the therapy.
  • The dimension of the lesion and age at initiation of treatment are the most important factors affecting the response to treatment.
  • [MeSH-major] Hemangioma / drug therapy. Methylprednisolone / therapeutic use. Prednisolone / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205840.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


37. Vlahovic A, Simic R, Djokic D, Ceran C: Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: a case report. J Pediatr Hematol Oncol; 2009 Nov;31(11):858-60
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: a case report.
  • There were 63 cutaneous hemangiomas over the scalp, face, trunk, and extremities.
  • Computed tomography scan revealed the presence of hemangiomas in the liver and kidneys; laryngobronchoscopy identified the presence of hemangioma in tracheobronchial tree.
  • Treatment with corticosteroids, in dose of 3 mg/kg/d intravenously, was initiated.
  • Magnetic resonance imaging of the abdomen revealed the marked decrease in size of the liver hemangioma.
  • After 3 years of follow-up the child is well developed, fully recovered, without cardiologic or respiratory problems.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Hemangioma / drug therapy. Hemangioma / pathology. Mesna / administration & dosage. Protective Agents / administration & dosage

  • Genetic Alliance. consumer health - Diffuse Neonatal Hemangiomatosis.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19829152.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Protective Agents; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna
  •  go-up   go-down


38. Denoyelle F, Leboulanger N, Enjolras O, Harris R, Roger G, Garabedian EN: Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol; 2009 Aug;73(8):1168-72
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
  • There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol.
  • The current study aims to assess efficacy of systemic Propranolol for subglottic hemangiomas and to discuss its place among the other available therapies.
  • We report 2 infants with subglottic hemangiomas, which were resistant to other established medical treatments.
  • One infant presented with PHACES association, the other with widespread cutaneous congenital hemangiomas.
  • Both patients' subglottic hemangiomas responded dramatically to systemic Propranolol.
  • No side effects of the therapy occurred, and a safety protocol previously designed for Propranolol prescribed for other indications was applied to our patients.
  • Propranolol appears to be an effective treatment for subglottic hemangiomas and should now be used as a first-line treatment in subglottic hemangiomas when intervention is required.
  • [MeSH-major] Adrenergic beta-Antagonists / therapeutic use. Hemangioma / drug therapy. Laryngeal Neoplasms / drug therapy. Propranolol / therapeutic use. Tracheal Neoplasms / drug therapy
  • [MeSH-minor] Abnormalities, Multiple. Female. Humans. Infant. Skin Neoplasms

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19481268.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


39. Satoh S, Yamazaki M, Yahikozawa H, Ichikawa N, Saito H, Hanyuu N, Hata S, Hachyou M: Intravascular large B cell lymphoma diagnosed by senile angioma biopsy. Intern Med; 2003 Jan;42(1):117-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B cell lymphoma diagnosed by senile angioma biopsy.
  • We performed a skin biopsy from two typical senile angiomas.
  • In one of these biopsy specimens, a capillary hemangioma was present in the mid-reticular dermis and it was filled with abnormal B cells.
  • The diagnosis of intravascular B cell lymphoma (IVL) was thus established.
  • However, it is recently thought that if the diagnosis is established early, aggressive chemotherapy increases survival.
  • Senile angioma is a skin eruption that is considered prevalent for the most part in elderly people.
  • If a patient is suspected to have IVL, and there is no appropriate site of biopsy, it might be beneficial to try a skin biopsy aiming at senile angiomas for early diagnosis.
  • [MeSH-major] Hemangioma, Capillary / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Skin Neoplasms / diagnosis. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Angioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12583632.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Metry DW, Hebert AA: Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol; 2000 Jul;136(7):905-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cutaneous vascular tumors of infancy: when to worry, what to do.
  • OBJECTIVES: To discuss the current knowledge regarding complicated hemangiomas (cervicofacial, periorbital, lumbosacral, and parotid), including the associated syndromes of diffuse neonatal hemangiomatosis and PHACES (posterior fossa malformations, most commonly of the Dandy-Walker variant; hemangiomas [especially large, plaquelike, facial lesions]; arterial anomalies; cardiac anomalies and coarctation of the aorta; eye abnormalities; and sternal cleft and/or supraumbilical raphe).
  • To discuss 2 newly recognized entities that may be a source of diagnostic confusion with the common hemangioma, the kaposiform hemangioendothelioma and tufted angioma.
  • To discuss the risks and benefits of current treatment options, including the use of systemic corticosteroids and interferon in necessary situations.
  • CONCLUSIONS: The common hemangioma, kaposiform hemangioendothelioma, and tufted angioma, though benign histologically, may cause serious consequences for children.
  • Dermatologists should also be aware of available treatment options, including the use of systemic chemotherapy in life-threatening situations.
  • [MeSH-major] Hemangioma. Skin Neoplasms
  • [MeSH-minor] Abnormalities, Multiple. Hemangioendothelioma / congenital. Hemangioendothelioma / diagnosis. Hemangioendothelioma / pathology. Hemangioendothelioma / therapy. Humans. Infant. Infant, Newborn. Syndrome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10890993.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


41. de Mesquita CJ: About strawberry, crab claws, and the Sir James Black's invention. Hypothesis: can we battle keloids with propranolol? Med Hypotheses; 2010 Feb;74(2):353-9
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cutaneous hemangiomas of infancy or infantile hemangiomas are the most common benign tumor of childhood.
  • They were formerly known as strawberry hemangiomas in reason of its typical appearance although uncommon morphologic variations can be found.
  • Usually hemangiomas are harmless growths that are the result of proliferation of endothelial cells during early childhood.
  • Occasionally, infantile hemangiomas suffer dramatic overgrowth causing esthetical damages, as well compromises to vital structures that requires prompt intervention.
  • Propranolol, a beta-adrenergic receptor antagonist that was invented by Sir James Black in 1960s, appears to be an effective treatment for infantile hemangiomas and should now be used as a first-line treatment in hemangiomas when intervention is required.
  • Keloids (that resembles crab claws) and hypertrophic scars are fibrous tissue outgrowths that result from a derailment in the normal wound-healing process.
  • Systemic or intralesional propranolol may play a role in the amelioration of keloids and hypertrophic scars due to their potential to induce vasoconstriction of over proliferating tissues, triggering apoptosis of endothelial cells and also to their effect as modulator of inflammatory process during wound healing.
  • [MeSH-major] Keloid / drug therapy. Keloid / metabolism. Models, Biological. Propranolol / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758768.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vasodilator Agents; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


42. Schiavetti A, De Pasquale MD, Di Salvo S, Ventriglia F, Clerico A: Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report. Pediatr Hematol Oncol; 2003 Mar;20(2):161-5
Hazardous Substances Data Bank. FUROSEMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four cutaneous angiomas were noted.
  • Instrumental examinations revealed congestive heart failure and multiple focal lesions in the liver with typical features of hemangiomas.
  • The therapy with subcutaneous interferon-alfa-2a (IFN-alpha) was administered for 12 months with progressive regression of cutaneous hemangiomas, liver lesions, and cardiological alterations.
  • IFN-alpha therapy was effective without any significant adverse effects.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Heart Failure / etiology. Hemangioma / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / congenital. Abdominal Neoplasms / drug therapy. Digitalis Glycosides / therapeutic use. Diuretics / therapeutic use. Dyspnea / etiology. Female. Furosemide / therapeutic use. Head and Neck Neoplasms / congenital. Head and Neck Neoplasms / drug therapy. Heart Septal Defects, Atrial / complications. Heel. Hemangioma, Capillary / congenital. Hemangioma, Capillary / drug therapy. Hemangioma, Cavernous / congenital. Hemangioma, Cavernous / drug therapy. Hepatomegaly / etiology. Humans. Infant. Knee. Neoplasms, Multiple Primary / congenital. Neoplasms, Multiple Primary / drug therapy. Recombinant Proteins. Remission Induction

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12554528.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Digitalis Glycosides; 0 / Diuretics; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


43. Wasong SJ, Klepeiss SA, Zaenglein AL: Picture of the month. Ulcerated infantile hemangioma. Arch Pediatr Adolesc Med; 2008 Sep;162(9):893-4
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Picture of the month. Ulcerated infantile hemangioma.
  • [MeSH-major] Hemangioma, Capillary / diagnosis. Scrotum / blood supply. Skin Ulcer / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Drug Therapy, Combination. Gentamicins / therapeutic use. Humans. Infant. Male. Mupirocin / therapeutic use. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18762610.001).
  • [ISSN] 1538-3628
  • [Journal-full-title] Archives of pediatrics & adolescent medicine
  • [ISO-abbreviation] Arch Pediatr Adolesc Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gentamicins; 9PHQ9Y1OLM / Prednisolone; D0GX863OA5 / Mupirocin
  •  go-up   go-down


44. Grantzow R, Schmittenbecher P, Cremer H, Höger P, Rössler J, Hamm H, Hohenleutner U: Hemangiomas in infancy and childhood. S 2k Guideline of the German Society of Dermatology with the working group Pediatric Dermatology together with the German Society for Pediatric Surgery and the German Society for Pediatric Medicine. J Dtsch Dermatol Ges; 2008 Apr;6(4):324-9
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiomas in infancy and childhood. S 2k Guideline of the German Society of Dermatology with the working group Pediatric Dermatology together with the German Society for Pediatric Surgery and the German Society for Pediatric Medicine.
  • [MeSH-major] Hemangioma / congenital. Infant, Premature, Diseases / therapy. Skin Neoplasms / congenital
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Cross-Sectional Studies. Cryosurgery. Diagnosis, Differential. Dose-Response Relationship, Drug. Esthetics. Female. Humans. Infant. Infant, Newborn. Low-Level Light Therapy. Male. Prednisolone / administration & dosage. Syndrome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Premature Babies.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312432.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Germany
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


45. Aldecoa Bilbao V, Viaplana Bartolí G, Teodoro Marín S, Perich Durán RM: [Hypertrophic myocardiopathy associated with oral corticosteroids in an infant with cutaneous hemangioma]. An Pediatr (Barc); 2008 Feb;68(2):197-8
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hypertrophic myocardiopathy associated with oral corticosteroids in an infant with cutaneous hemangioma].
  • [Transliterated title] Miocardiopatía hipertrófica asociada a corticoides orales en lactante afectada de hemangioma cutáneo.
  • [MeSH-major] Cardiomyopathy, Hypertrophic / chemically induced. Glucocorticoids / adverse effects. Hemangioma / drug therapy. Prednisolone / adverse effects. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341893.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down






Advertisement